Blood Coagulation

Introduction

• Blood coagulation is a tightly regulated process triggered by vascular injury through intrinsic and extrinsic pathways, leading to thrombin formation and fibrin clot development. Platelets stabilize the clot, while fibrinolysis limits its spread. Imbalance may result in disorders such as disseminated intravascular coagulation.
• Blood coagulation is an essential physiological process that prevents excessive blood loss after vascular injury.
• Blood normally remains in a fluid state within vessels but rapidly forms a clot when damage occurs.
• Failure of coagulation results in hemorrhage, while excessive activation may cause thromboembolic complications.
• Immediately after injury, a platelet plug forms and provides temporary control of bleeding.
• This initial plug is unstable and requires reinforcement by fibrin formation.
• Definitive hemostasis involves conversion of fibrinogen to fibrin, producing a stable clot.
• Coagulation is mediated by plasma clotting factors that circulate in inactive forms.
• These factors are sequentially activated through enzyme cascades at the site of injury.
• The process ensures rapid sealing of vascular defects while preserving normal blood flow elsewhere.

Clotting Factors

• Clotting factors are plasma proteins that participate in a sequential enzymatic cascade leading to fibrin clot formation.
• They are mostly synthesized in the liver and circulate in inactive forms until activated at the site of injury.
• Traditionally, clotting factors are numbered I to XIII, with factor VI no longer recognized as a separate entity.

Factor I

• Fibrinogen is a soluble plasma glycoprotein essential for clot formation.
• It is composed of three paired polypeptide chains and is synthesized in the liver.
• Normal plasma concentration ranges from 2000 to 4000 micrograms per milliliter.
• Thrombin converts fibrinogen into insoluble fibrin strands.
• Activated factor XIII stabilizes fibrin by cross-linking.
• Fibrin provides the structural framework of the clot.
• It is an acute phase protein and increases during inflammation.

Factor II

• Prothrombin is a vitamin K-dependent protein produced in the liver.
• It is converted to thrombin by activated factor X in the presence of cofactors.
• Thrombin plays a central role in coagulation.
• It converts fibrinogen into fibrin and activates platelets.
• It also activates several clotting factors, amplifying the cascade.
• Thrombin contributes to regulation by activating anticoagulant pathways.
• Its activity is inhibited by antithrombin and related inhibitors.

Factor III

• Tissue factor is a membrane-bound protein expressed in subendothelial tissues.
• It is not normally exposed to circulating blood.
• Vascular injury exposes tissue factor to blood components.
• It binds with factor VII and forms an active complex.
• This complex activates factor X and initiates the extrinsic pathway.

Factor IV

• Calcium ions are essential cofactors in multiple steps of coagulation.
• They facilitate activation of several clotting factors.
• Calcium is particularly important for conversion of prothrombin to thrombin.
• It also stabilizes interactions between coagulation proteins and phospholipid surfaces.

Factor V

• Factor V is a large plasma glycoprotein synthesized in the liver.
• It acts as a cofactor for factor X in the conversion of prothrombin to thrombin.
• Activation of factor V significantly accelerates thrombin formation.
• It also participates in amplification of the coagulation cascade.
• Deficiency of factor V impairs clot formation and leads to bleeding tendency.
• Together, these clotting factors interact in a coordinated manner to ensure efficient and localized blood coagulation while preventing excessive thrombosis.

Table 21.1: Clotting factors.

Category	Components (Key Terms)
Primary Clotting Factors	Factor I (Fibrinogen), Factor II (Prothrombin), Factor III (Tissue factor), Factor IV (Calcium), Factor V (Proaccelerin)
Enzymatic Cascade Factors	Factor VII, Factor VIII, Factor IX, Factor X, Factor XI, Factor XII, Factor XIII
Supporting Molecules	High-molecular-weight kininogen, Prekallikrein, Kallikrein, Platelet phospholipid
Regulatory Inhibitors	Protein C, Protein Z, Thrombomodulin, Antithrombin, Tissue factor pathway inhibitor

Factor VII

• Factor VII is a vitamin K-dependent clotting protein synthesized in the liver.
• It is a single-chain polypeptide circulating in inactive form.
• It has a short half-life of about 3 to 6 hours, making it sensitive to deficiency states.
• It is activated upon binding with tissue factor at sites of vascular injury.
• The factor VII–tissue factor complex initiates the extrinsic pathway.
• Its main function is to activate factor X to Xa.
• It can also activate factor IX, linking extrinsic and intrinsic pathways.
• Its activity is regulated by tissue factor pathway inhibitor.

Factor VIII

• Factor VIII is an essential coagulation protein associated with von Willebrand factor in plasma.
• It is encoded on the X chromosome and shows genetic linkage to sex-linked disorders.
• It is mainly produced in endothelial cells and the liver.
• Its half-life is about 8 to 12 hours when bound to von Willebrand factor.
• It is activated by thrombin or factor Xa during coagulation.
• Activated factor VIII functions as a cofactor for factor IXa.
• Together, they convert factor X to Xa in the intrinsic pathway.
• Reduced levels of factor VIII impair clot formation and lead to bleeding tendency.

Factor IX

• Factor IX is a vitamin K-dependent protein synthesized in the liver.
• It circulates as an inactive zymogen with a half-life of 18 to 24 hours.
• It is encoded on the X chromosome and associated with inherited bleeding disorders.
• It is activated by factor XIa or by the tissue factor–factor VIIa complex.
• Activated factor IX works with factor VIIIa on platelet surfaces.
• This complex efficiently activates factor X in the intrinsic pathway.
• Platelet membranes provide a phospholipid surface essential for its action.

Factor X

• Factor X is a vitamin K-dependent coagulation factor produced in the liver.
• It has a half-life of approximately 30 to 40 hours in plasma.
• It represents the point of convergence of intrinsic and extrinsic pathways.
• It is activated by factor IXa in the intrinsic pathway and by factor VIIa in the extrinsic pathway.
• Activated factor X forms a complex with factor V on platelet surfaces.
• This complex converts prothrombin to thrombin.
• Thrombin generation is crucial for fibrin formation and clot stabilization.
• Factor Xa is inhibited by antithrombin, and this inhibition is enhanced by heparin.

Factor XI

• Factor XI is a coagulation protein synthesized in the liver.
• It belongs to the group of contact factors, along with factor XII, prekallikrein, and high-molecular-weight kininogen.
• Its gene is located on chromosome 4.
• It is activated by factor XIIa, with facilitation by high-molecular-weight kininogen.
• Activated factor XI converts factor IX to IXa in the intrinsic pathway.
• It is regulated by plasma protease inhibitors such as antithrombin and α1-protease inhibitor.
• Deficiency leads to mild to moderate bleeding tendency.

Factor XII

• Factor XII is a plasma protein activated by contact with negatively charged surfaces.
• It is also called the contact activation factor.
• Its gene is located on chromosome 5.
• Activation occurs in the presence of high-molecular-weight kininogen and prekallikrein.
• Activated factor XII initiates the intrinsic pathway by activating factor XI.
• Despite its role in laboratory coagulation tests, deficiency rarely causes clinical bleeding.

Factor XIII

• Factor XIII is responsible for stabilizing the fibrin clot.
• It is a glycoprotein composed of A and B subunits.
• The A subunit has enzymatic activity and belongs to the transglutaminase family.
• It is present in plasma, platelets, monocytes, and macrophages.
• Thrombin activates factor XIII in the presence of calcium.
• Activated factor XIII forms covalent cross-links between fibrin strands.
• This cross-linking increases clot strength and resistance to fibrinolysis.
• Deficiency results in unstable clots and delayed bleeding.
• It also contributes to wound healing and maintenance of pregnancy.

HMW Kininogen

• High-molecular-weight kininogen is a nonenzymatic plasma cofactor involved in coagulation.
• It circulates bound to factor XI and prekallikrein as part of the contact system.
• It is synthesized in the liver and encoded on chromosome 3.
• Its plasma half-life is approximately 150 hours.
• It facilitates activation of factor XII and prekallikrein.
• It is cleaved to release bradykinin, a potent vasodilator involved in inflammation.
• It also exhibits inhibitory activity against certain proteases.

H4: Prekallikrein

• Prekallikrein is a liver-derived plasma protein participating in the contact phase of coagulation.
• It is encoded on chromosome 4 and has a half-life of about 35 hours.
• It circulates in complex with high-molecular-weight kininogen and factor XI.
• Upon activation, it is converted to kallikrein.
• Kallikrein amplifies activation of factor XII, enhancing coagulation.
• It also contributes to inflammatory responses through bradykinin generation.

Thrombomodulin

• Thrombomodulin is a transmembrane protein expressed on endothelial cells.
• It acts as a cofactor that modifies the function of thrombin.
• When thrombin binds to thrombomodulin, its procoagulant activity is reduced.
• The complex activates protein C, which inactivates factors V and VIII.
• This mechanism provides an important anticoagulant effect.
• Thrombomodulin also promotes activation of fibrinolysis regulators.
• Thus, it maintains balance between clot formation and dissolution.

Protein C

• Protein C is a vitamin K-dependent plasma protein with anticoagulant function.
• It is synthesized in the liver and encoded on chromosome 2.
• It has a molecular weight of about 59,000 and a half-life of nearly 6 hours.
• It is activated when thrombin binds to thrombomodulin on endothelial cells.
• Activated protein C inactivates factors Va and VIIIa.
• This action reduces thrombin generation and limits clot formation.
• It plays a crucial role in maintaining balance between coagulation and anticoagulation.

Protein S

• Protein S is a glycoprotein mainly produced in the liver and also in endothelial and other cells.
• It has a molecular weight of about 75,000 and a half-life of approximately 40 hours.
• It is encoded on chromosome 3.
• Protein S acts as a cofactor for activated protein C.
• The protein C–protein S complex inactivates factors Va and VIIIa.
• It also exerts independent anticoagulant activity by interfering with factor Xa binding.
• It is essential for effective regulation of coagulation.

Protein Z

• Protein Z is a vitamin K-dependent protein synthesized in the liver.
• It has a half-life of about 60 hours and is encoded on chromosome 3.
• It functions as a cofactor in anticoagulant pathways.
• It enhances inhibition of factor Xa through specific protease inhibitors.
• Thus, it contributes to regulation of blood coagulation and prevention of thrombosis.

Tissue Factor Pathway Inhibitor (TFPI)

• Tissue factor pathway inhibitor is a single-chain protein produced mainly by endothelial cells.
• It has a molecular weight of about 35,000 and is encoded on chromosome 2.
• It contains protease inhibitor domains that block factor Xa and factor VIIa, thereby limiting extrinsic pathway activity.

Antithrombin III (AT-III)

• Antithrombin III is a serine protease inhibitor produced mainly in the liver.
• It is encoded on chromosome 1 and regulates coagulation.
• It inhibits thrombin, factor Xa, and factor IXa.
• Its activity is markedly enhanced by heparin.
• It can also inhibit the tissue factor–factor VIIa complex.

Mechanism Of Blood Coagulation

• Blood coagulation proceeds through three coordinated stages that ensure effective clot formation.
  • Stage 1: Activation of factor X leads to formation of the prothrombin activator complex.
  • Stage 2: Prothrombin is converted into thrombin.
  • Stage 3: Thrombin converts fibrinogen into fibrin, forming the clot.

Activation of Stuart-Prower Factor (Factor X)

• Activation of factor X is the central event in coagulation.
• Factor Xa initiates conversion of prothrombin to thrombin.
• This activation occurs through two pathways: intrinsic and extrinsic pathways.

Intrinsic Pathway

• The intrinsic pathway is initiated when blood contacts a negatively charged surface or exposed collagen after vascular injury.
• It proceeds through a sequence of enzyme-mediated reactions leading to activation of factor X.

Step 1 (Activation of XII)

• Contact with subendothelial collagen activates factor XII.
• High-molecular-weight kininogen and kallikrein act as cofactors in this process.
• Platelet adhesion and aggregation occur simultaneously at the injury site.

Step 2 (Activation of XI)

• Activated factor XII converts factor XI to factor XIa.
• This step is enhanced by high-molecular-weight kininogen.

Step 3 (Activation of IX)

• Factor XIa converts factor IX to factor IXa.
• Calcium ions facilitate this reaction.
• Activated factor IX interacts with other cofactors on platelet surfaces.

Step 4 (Activation of X)

• Factor IXa, along with factor VIIIa, calcium, and phospholipids, activates factor X to Xa.
• This step leads to formation of the prothrombin activator complex.

Formation of VIIIa is crucial in Stage 1

• Factor VIII circulates bound to von Willebrand factor.
• It becomes active after dissociation and activation by thrombin or factor Xa.
• Activated factor VIII enhances activation of factor X.
• This creates a positive feedback loop that amplifies coagulation.

Enzyme Cascade Hypothesis

• Each activated factor acts as an enzyme to activate the next factor.
• This sequential amplification is known as the enzyme cascade.
• It ensures rapid and efficient clot formation at the site of injury.

Extrinsic Pathway

• The extrinsic pathway is rapidly initiated following tissue injury.
• It depends on factors released from damaged tissues outside the bloodstream.

Step 1 (Release of TPL)

• Injury leads to release of tissue factor from subendothelial cells.
• Tissue factor acts as the primary trigger for this pathway.
• It is normally not exposed to circulating blood.

Step 2 (Activation of VII)

• Tissue factor binds to factor VII and converts it to factor VIIa.
• This is the key activating step in the extrinsic pathway.
• Factor VIIa can activate both factor X and factor IX.
• This interaction links the extrinsic and intrinsic pathways..

Step 3 (Activation of X)

• The tissue factor–factor VIIa complex converts factor X to factor Xa.
• Calcium ions and platelet phospholipids enhance this reaction.
• Factor Xa initiates formation of the prothrombin activator complex.
• The intrinsic and extrinsic pathways function together as an integrated system to maintain effective hemostasis.

Formation of Thrombin from Prothrombin

• The second stage of coagulation involves conversion of prothrombin to thrombin.
• Activated factor X forms a complex with factor V, calcium, and platelet phospholipids.
• Factor V acts as a cofactor and accelerates this reaction.
• Thrombin generation is essential for subsequent fibrin formation.

Functions of Thrombin in Blood Coagulation

• Thrombin converts fibrinogen into fibrin by removing fibrinopeptides, leading to clot formation.
• Fibrin monomers polymerize to form a stable fibrin network.
• It activates factors V, VIII, and XIII, producing positive feedback in the coagulation cascade.
• It is a potent activator of platelets, enhancing aggregation and clot stability.
• Thrombin activates enzymes that reduce fibrinolysis, thereby preserving the clot.
• It also exhibits anticoagulant action by binding to thrombomodulin and activating protein C.
• This dual role helps maintain balance between clot formation and breakdown.
• Thrombin contributes to vascular repair through growth factor–like effects.
• It participates in inflammation and tissue healing processes.
• The primary inhibitor of thrombin is antithrombin, and its action is enhanced by heparin.

Formation of Fibrin from Fibrinogen

• The final stage of coagulation involves conversion of fibrinogen into fibrin, forming a stable clot.
• This process is catalyzed by thrombin and occurs in three sequential steps.

Proteolysis of Soluble Fibrinogen

• Fibrinogen is a soluble plasma protein with central and peripheral domains.
• Thrombin cleaves fibrinogen by removing fibrinopeptides A and B.
• This cleavage produces fibrin monomers.
• These monomers are reactive and ready for polymer formation.

Polymerization of Fibrin Monomers

• Fibrin monomers spontaneously combine to form protofibrils.
• Multiple protofibrils aggregate to form thick fibrin fibers.
• These fibers branch and create a mesh-like network.
• Thrombin also activates factor XIII during this stage.
• The developing fibrin network provides the initial framework of the clot.

Stabilization of Fibrin Polymer

• Factor XIIIa stabilizes fibrin by forming covalent cross-links between fibrin strands.
• Thrombin activates factor XIII in the presence of calcium ions.
• Cross-linking increases the mechanical strength and durability of the clot.
• The stabilized fibrin meshwork traps red blood cells and platelets.
• This forms a firm and effective hemostatic plug.
• The coordinated sequence of proteolysis, polymerization, and stabilization ensures formation of a strong and localized blood clot, preventing further blood loss.

Clot Retraction

• Clot retraction is the process by which a formed blood clot contracts and expels serum.
• The clot consists of a fibrin network trapping red cells and platelets.
• Fibrin strands attach to the vessel wall and stabilize the clot.
• Within minutes to hours, the clot shrinks and becomes compact.
• This process also occurs in vivo, leading to consolidation of the thrombus.
• Platelets play a central role in clot retraction.
• Adequate number and normal function of platelets are essential for this process.
• Platelet-rich clots are more resistant to fibrinolysis.

Mechanism of Clot Retraction

• Platelets extend filopodia that attach to fibrin strands.
• Fibrin fibers interact with platelet cytoskeletal elements.
• Platelet contraction pulls fibrin strands inward.
• This leads to compaction and internalization of fibrin within platelets.
• Thrombin and calcium ions enhance this contraction.
• Platelet membrane receptors such as glycoprotein IIb/IIIa facilitate this interaction.

Functions of Clot Retraction

• The retracted clot forms a firm and stable hemostatic plug.
• It effectively seals the injured blood vessel.
• It promotes wound healing by bringing wound edges closer.
• It reduces susceptibility of the clot to fibrinolysis.

Prolongation of Clot Retraction Time

• Clot retraction normally begins within about 30 minutes after clot formation.
• Approximately 50 percent retraction occurs within one hour.
• Complete retraction is achieved within 18 to 24 hours.
• Reduced retraction at one hour indicates abnormal platelet function.

Clinical Significance

• Platelet deficiency leads to impaired clot retraction.
• Defects in platelet receptors, especially glycoprotein IIb/IIIa, reduce clot contraction.
• Prolonged clot retraction time suggests platelet dysfunction and increased bleeding risk.

Anticlotting Mechanism (Fibrinolysis)

• The body maintains a balance between coagulation and anticlotting mechanisms to prevent unwanted clot formation.
• Under normal conditions, a low level of clotting activity occurs due to minor vascular stress.
• Significant clot formation occurs only when sufficient thrombin is generated after injury.
• Basal coagulation is counteracted by continuous anticoagulant activity in circulation.
• Low levels of protein C and tissue plasminogen activator indicate ongoing fibrinolytic control.
• Naturally occurring anticoagulants regulate clotting by inhibiting activated clotting factors.
• A balance exists between thromboxane A2 and prostacyclin, which respectively promote and inhibit platelet aggregation.
• The vascular endothelium plays a key role by releasing substances that prevent platelet adhesion and promote fibrinolysis.
• These coordinated mechanisms ensure that clotting remains localized and does not obstruct normal blood flow.

Mechanism of Fibrinolysis

• Fibrinolysis is activated along with coagulation to limit clot formation to the site of injury.
• It prevents excessive intravascular thrombosis and maintains vascular patency.
• The process occurs in three coordinated steps.

Activation of Protein C

• Protein C is activated by thrombin bound to thrombomodulin on endothelial cells.
• This mechanism converts thrombin into an anticoagulant mediator.
• Activated protein C regulates coagulation by inhibiting key clotting factors.

Activation of Plasmin

• Activated protein C reduces inhibitors of plasminogen activators.
• This promotes conversion of plasminogen to plasmin.
• Protein C, along with protein S, also inactivates factors Va and VIIIa.
• These actions reduce further thrombin generation and limit clot propagation.

Fibrinolysis

• Plasmin is the main enzyme responsible for breakdown of fibrin.
• It degrades fibrin into soluble fibrin degradation products.
• Tissue plasminogen activator and urokinase enhance plasmin formation.
• Thrombin also indirectly supports regulation of fibrinolysis.
• The overall process ensures controlled removal of clots after vessel repair, maintaining a balance between coagulation and anticoagulation.

Functions of Plasmin

• Plasmin is a proteolytic enzyme responsible for clot breakdown and other physiological processes.

Fibrinolytic Actions

• Plasmin degrades both fibrin and fibrinogen.
• It initially cleaves specific polypeptide chains, producing intermediate fragments.
• Further cleavage generates smaller fragments such as D and E components.
• Degradation of fibrin produces fibrin degradation products, including D-dimer.
• These products are useful markers of fibrinolytic activity in clinical practice.

Nonfibrinolytic Actions

• Plasmin participates in tissue remodeling and wound healing.
• It contributes to inflammatory responses and cellular migration.
• It facilitates tumor cell invasion by degrading extracellular matrix.
• It plays a role in reproductive processes such as ovulation and embryonic development.
• It is involved in neuronal development and regeneration.
• Plasmin also activates certain growth factors and supports vascular repair.

Plasminogen

• Plasminogen is an inactive precursor of plasmin synthesized mainly in the liver.
• It is a polypeptide with molecular weight about 92,000 and half-life of nearly two days.
• It consists of heavy and light chains formed after activation.
• The gene is located on chromosome 6.
• Activation occurs by cleavage through plasminogen activators.
• This conversion produces plasmin, an active enzyme responsible for fibrinolysis.

Plasminogen Activators

• Plasminogen activators convert plasminogen into plasmin, initiating fibrinolysis.
• The two main endogenous activators are tissue plasminogen activator and urokinase.

Tissue Plasminogen Activator (t-PA)

• Tissue plasminogen activator is produced mainly by endothelial cells.
• It is a polypeptide with a short half-life of about 5 minutes.
• Its gene is located on chromosome 8.
• Its release is stimulated by mediators such as thrombin, histamine, and bradykinin.
• Alone, it has limited activity, but its effect increases significantly in the presence of fibrin.
• Fibrin enhances binding between tissue plasminogen activator and plasminogen.
• This ensures localized fibrinolysis at the site of clot formation.

Urokinase and Streptokinase

• Urokinase is produced by endothelial cells, macrophages, and renal epithelial cells.
• It exists in two forms with different molecular weights.
• Both forms activate plasminogen, but only one form binds to specific cell receptors.
• It is an effective activator even without fibrin, though it has lower fibrin affinity than tissue plasminogen activator.
• These activators regulate fibrinolysis, ensuring timely removal of clots after healing.

Inhibitors of Fibrinolysis

• Fibrinolysis inhibitors regulate clot breakdown and prevent excessive bleeding.
• They are classified into plasmin inhibitors and plasminogen activator inhibitors.

Plasmin Inhibitors

• Plasmin is inhibited by serine protease inhibitors, which form stable inactive complexes.
• Alpha-2 antiplasmin is the main inhibitor and is produced in the liver and kidneys.
• It is also present in platelet granules and rapidly neutralizes plasmin.
• Alpha-2 macroglobulin is another inhibitor produced by endothelial cells and macrophages.

Plasminogen-Activator Inhibitors (PAI)

• Plasminogen activator inhibitor-1 is the most important physiological inhibitor.
• It is secreted by liver, endothelial cells, monocytes, and adipose tissue.
• It inhibits tissue plasminogen activator and urokinase.
• Plasminogen activator inhibitor-2 is less potent and is produced by placenta and immune cells.
• These inhibitors maintain balance between clot formation and fibrinolysis.

Plasmin Generation Defects

• Disorders of plasmin generation alter the balance between clot formation and breakdown.

Fibrinolytic Deficiency

• Plasminogen deficiency reduces fibrinolytic activity.
• Type 1 deficiency shows reduced level and function of plasminogen.
• Type 2 deficiency shows normal level but reduced functional activity.
• Patients develop recurrent venous thrombosis, including pulmonary embolism.
• Defects in plasminogen activators also impair fibrinolysis.

Enhanced Fibrinolysis

• Excess fibrinolysis usually results from reduced inhibitor activity.
• Alpha-2 antiplasmin deficiency is a major cause.
• Patients present with increased bleeding tendency.
• Acquired deficiency may occur in liver disease, disseminated intravascular coagulation, nephrotic conditions, and during thrombolytic therapy.
• Increased plasmin activity leads to excessive clot breakdown and hemorrhage.

Regulation of Blood Coagulation

• Blood coagulation at the site of injury is a protective physiological process that prevents excessive loss of blood volume and maintains circulatory stability.
• After formation of the fibrin–platelet plug, the coagulation process must be appropriately limited to avoid unnecessary extension of clot formation.
• Uncontrolled coagulation can lead to intravascular thrombosis, which may obstruct blood flow in otherwise normal vessels.
• Maintenance of blood in a fluid state within intact vessels is essential for adequate tissue perfusion and oxygen delivery.
• A precise balance between procoagulant and anticoagulant mechanisms ensures normal hemostasis without pathological clotting.
• Dynamic blood flow plays a major role in preventing clot formation within vessels.
• Continuous circulation dilutes activated clotting factors and prevents their local accumulation.
• Reduced blood flow, such as in vascular stasis, promotes coagulation activation and thrombus formation. Therefore, maintenance of normal flow velocity is essential to prevent intravascular clotting.
• The vascular endothelium is a critical regulator that restricts coagulation to the site of injury.
• Endothelial damage exposes collagen and negatively charged surfaces, which initiate the clotting cascade.
• Intact endothelium exhibits antithrombotic properties that prevent unnecessary clot formation.
• Endothelial cells release thrombomodulin, which activates the protein C–protein S system, leading to inactivation of clotting factors Va and VIIIa.
• They also express inhibitors such as antithrombin III and tissue factor pathway inhibitor on their surface.
• Endothelium secretes prostacyclin and nitric oxide, which inhibit platelet aggregation and activation.
• The heparin–antithrombin III system acts as an important natural anticoagulant pathway.
• Heparin, released from mast cells and basophils, enhances the activity of antithrombin III.
• Activated antithrombin III inhibits several clotting factors, including factors IXa, Xa, XIa, and XIIa. This mechanism limits excessive propagation of the coagulation cascade.
• Thrombin plays a dual role in coagulation regulation.
• While it promotes fibrin formation, it also initiates anticoagulant pathways through activation of protein C. This represents a negative feedback mechanism that prevents excessive clot formation. Thus, coagulation is a tightly regulated and self-limiting process.
• The liver has a central role in maintaining hemostatic balance.
• Most clotting factors are synthesized in the liver as plasma proteins.
• Liver dysfunction leads to prolonged clotting time due to reduced production of these factors.
• The liver also removes activated clotting factors from circulation, preventing systemic coagulation. This clearance mechanism becomes more active when coagulation is excessively stimulated.
• Platelets contribute significantly to both initiation and regulation of coagulation.
• Upon activation, platelets expose phospholipid surfaces that facilitate assembly of clotting factor complexes.
• Platelet-derived factors enhance activation of factors V, VIII, and XI, accelerating clot formation.
• Activated platelets provide a surface for formation of factor IXa–VIIIa complex, leading to activation of factor X.
• Factor X activation is a key step in the coagulation cascade, resulting in thrombin generation.
• Platelet adhesion and aggregation are localized to the site of injury, ensuring that clotting remains spatially restricted.
• Overall, the interplay between endothelial function, blood flow, liver activity, plasma inhibitors, and platelets maintains a delicate equilibrium between coagulation and anticoagulation. This balance is essential to prevent both excessive bleeding and pathological thrombosis.

Anticoagulants

• Anticoagulants are substances that prevent blood from clotting by inhibiting various steps in the coagulation cascade.
• They are widely used in clinical and laboratory settings for specific purposes.
• They are essential for laboratory investigations, where unclotted blood samples are required for accurate analysis.
• They are used in blood preservation to maintain stored blood in a fluid state for transfusion.
• They are also employed in therapeutic anticoagulation to prevent or treat thromboembolic disorders.

Anticoagulants for Blood Collection

• Anticoagulants are added during venipuncture when whole blood samples are needed for testing.
• Commonly used agents include ethylenediaminetetraacetic acid, trisodium citrate, double oxalate, sodium fluoride, and heparin.
• Ethylenediaminetetraacetic acid is preferred for hematological investigations due to preservation of cellular morphology.
• Trisodium citrate is used for coagulation studies and blood storage in transfusion services.
• Heparin is used for blood gas and pH analysis, while sodium fluoride is used for plasma glucose estimation.

EDTA (Ethylenediamine Tetra-acetic Acid)

• The sodium and potassium salts of EDTA are widely used as potent anticoagulants in laboratory practice. It acts by chelating calcium ions, which are essential cofactors in multiple steps of the coagulation cascade.
• By forming a stable, non-ionized complex with calcium, it effectively prevents clot formation.
• The optimal concentration is about 1.2 milligrams per milliliter of blood for reliable anticoagulation.
• Excess EDTA causes cellular distortion, including shrinkage of red blood cells and degenerative changes in white blood cells. It reduces packed cell volume and increases mean corpuscular hemoglobin concentration due to altered cell integrity.
• Platelets may swell and fragment, producing falsely elevated platelet counts during analysis.

Sodium Citrate

• Trisodium citrate is commonly used for coagulation studies because of its reversible anticoagulant action. It prevents clotting by binding calcium ions in plasma.
• For tests such as prothrombin time and activated partial thromboplastin time, a ratio of 9 parts blood to 1 part citrate is maintained.
• For erythrocyte sedimentation rate estimation by the Westergren method, a 4:1 blood-to-citrate ratio is used.
• Accurate proportioning is essential to maintain validity of test results.

Double Oxalate

• Double oxalate contains ammonium oxalate and potassium oxalate in balanced proportions.
• Potassium oxalate causes red cell shrinkage, whereas ammonium oxalate causes cell swelling.
• Their combination maintains near-normal red cell volume, hence the term balanced oxalate.
• It is typically prepared as 1.2 percent ammonium oxalate and 0.8 percent potassium oxalate solution.
• Oxalates prevent coagulation by forming insoluble calcium salts, thereby removing free calcium from plasma.

Sodium Fluoride

• Sodium fluoride is primarily used for blood collection in glucose estimation.
• It inhibits glycolytic enzymes, thereby preventing breakdown of glucose after sample collection.
• Since it is a weak anticoagulant, it is usually combined with oxalate for effective action. This combination ensures both anticoagulation and preservation of glucose concentration.

Oxalates

• Oxalates of sodium, potassium, ammonium, or lithium act as anticoagulants by precipitating calcium ions.
• The removal of ionized calcium interrupts the coagulation pathway. However, they may alter cellular morphology and are therefore less preferred for detailed hematological studies.

Heparin

• Heparin is a naturally occurring anticoagulant present in the body. It acts by enhancing the activity of antithrombin, which inhibits thrombin and other clotting factors. This prevents conversion of fibrinogen to fibrin, thereby inhibiting clot formation. It is commonly used at a concentration of 10 to 20 international units per milliliter of blood.
• Heparin is preferred for blood gas analysis, pH measurement, and osmotic fragility testing. It is also used in clinical settings for anticoagulation therapy and in experimental studies to prevent clotting.

Anticoagulants for Treatment (Anticoagulation Therapy)

• Anticoagulants are used to prevent and treat thrombosis, which refers to formation of clots within blood vessels.
• They are indicated in venous thromboembolism, including deep vein thrombosis and pulmonary embolism.
• They are essential after placement of mechanical heart valves, where risk of clot formation is high.
• They help prevent embolic events in atrial fibrillation not related to valvular disease.
• They are used after cerebral ischemic episodes to reduce recurrence.
• They are beneficial in ischemic heart disease and peripheral vascular disorders.
• They are also used during placement of central venous catheters.
• Anticoagulants are administered as oral or parenteral agents.

Oral Anticoagulants

• Oral anticoagulants are drugs that reduce blood clot formation by interfering with specific steps in the coagulation cascade.
• They are commonly used for long-term prevention and treatment of thromboembolic disorders.
• Major groups include vitamin K antagonists, glycosaminoglycans, factor Xa inhibitors, and thrombin inhibitors.

Vitamin K Antagonists

• Warfarin is the most widely used oral vitamin K antagonist and belongs to the coumarin group. It acts by inhibiting the recycling of vitamin K, which is required for activation of certain clotting factors.
• Vitamin K–dependent factors include factor II, VII, IX, and X, which require γ-carboxylation for biological activity. This modification allows these factors to bind calcium and attach to phospholipid surfaces during coagulation.
• Warfarin reduces γ-carboxylation, leading to production of functionally inactive clotting factors. It inhibits enzymes responsible for regeneration of active vitamin K, thereby decreasing clotting efficiency.
• Reduced activity of these factors significantly impairs thrombin generation and fibrin formation.
• Warfarin also decreases activity of protein C and protein S, which are natural anticoagulants, during early therapy.
• Another vitamin K antagonist used clinically is dicoumarol.

Glycosaminoglycans

• Certain glycosaminoglycans can be administered orally and exhibit anticoagulant properties.
• They act by enhancing natural inhibitory pathways of coagulation.
• Their clinical use is less common compared to vitamin K antagonists.

Inhibitors of Factor Xa

• Factor Xa plays a central role in converting prothrombin to thrombin in the coagulation cascade.
• Selective inhibition of factor Xa reduces thrombin formation and limits clot development.
• These agents provide targeted anticoagulation with potentially fewer systemic effects.
• Their clinical application continues to expand with ongoing evaluation.

Inhibitors of Thrombin

• Thrombin inhibitors directly block the activity of thrombin, preventing conversion of fibrinogen to fibrin.
• They also reduce thrombin-mediated activation of other clotting factors and platelets.
• Many low-molecular-weight agents have been developed with improved specificity.
• These drugs are being increasingly used due to predictable pharmacological effects and reduced monitoring requirements.

Intravenous or Subcutaneous Anticoagulants

• Parenteral anticoagulants are administered by intravenous or subcutaneous routes for rapid and controlled anticoagulation.
• The most commonly used agents include heparin and hirudin, which act through different mechanisms.

Heparin

• Heparin is a naturally occurring glycosaminoglycan composed of repeating units of glucosamine and iduronic acid. It exists in forms with different molecular weights, broadly classified as low molecular weight and unfractionated heparin. Its anticoagulant effect is mediated by enhancing the activity of antithrombin, a plasma inhibitor of clotting enzymes.
• A specific pentasaccharide sequence in heparin binds strongly to antithrombin and increases its inhibitory action.
• Antithrombin inactivates key coagulation factors such as thrombin, factor Xa, and factor IXa.
• Unfractionated heparin forms a complex with both thrombin and antithrombin, facilitating efficient thrombin inhibition.
• In contrast, low molecular weight heparin primarily enhances inhibition of factor Xa and has less effect on thrombin.
• Low molecular weight heparin has more predictable pharmacokinetics and is commonly given subcutaneously. It is widely used in the management of venous thromboembolism and acute coronary conditions.

Hirudin

• Hirudin is a peptide anticoagulant consisting of about 65 amino acids. It acts as a direct thrombin inhibitor, binding to both the active site and fibrin-binding region of thrombin. This results in complete inhibition of thrombin activity and prevents fibrin formation. It is produced using recombinant techniques for clinical use.
• Hirudin is particularly useful in patients with heparin-induced thrombocytopenia, where heparin cannot be used. It has also been evaluated in conditions such as acute coronary syndromes and deep vein thrombosis.
• Overall, parenteral anticoagulants provide rapid anticoagulant action and are essential in acute clinical settings requiring immediate control of coagulation.

Investigations Of Bleeding Disorders

• Laboratory evaluation is indicated in patients with spontaneous bleeding or excessive bleeding after trauma or surgical procedures.
• Bleeding disorders arise from defects in formation of the primary hemostatic plug or the secondary hemostatic plug.
• Initial investigations aim to distinguish between platelet-related abnormalities and coagulation factor deficiencies.
• Tests for primary hemostasis assess platelet count and function.
• If a coagulation defect is suspected, further tests identify the deficient clotting factor.

Assessment of Defects in Temporary Hemostatic Plug

• Evaluation of the primary hemostatic plug focuses on platelet number, function, and capillary integrity.
• These tests help identify disorders related to platelets or small blood vessels.

Bleeding Time (BT)

• Bleeding time assesses platelet function and interaction with vascular endothelium.
• The normal value is 1 to 5 minutes by the Duke method and 5 to 11 minutes by the Ivy method.
• Prolongation indicates platelet deficiency or dysfunction, or vascular abnormalities.
• It is a simple screening test but has limited specificity and reproducibility.

Capillary Fragility Test

• This test evaluates the strength of capillary walls under increased pressure.
• A blood pressure cuff is inflated to about 100 millimeters of mercury for 5 minutes on the arm.
• Appearance of petechiae indicates capillary fragility.
• Normally, up to 10 petechiae may be seen.
• More than 10 petechiae suggest capillary weakness, thrombocytopenia, or both.

Platelet Aggregation Test

• This test measures the ability of platelets to aggregate in response to specific agonists.
• Platelet-rich plasma is exposed to aggregating agents such as adenosine diphosphate or collagen.
• Aggregation is recorded as a change in light transmission using an aggregometer. It is essential for diagnosing platelet function disorders.

Pletelet Adhesiveness Test

• This test evaluates the ability of platelets to adhere to artificial surfaces.
• Blood is passed through a column containing glass beads, and platelet retention is measured.
• The normal adhesiveness ranges from 75 percent to 95 percent retention.
• Reduced adhesiveness indicates impaired platelet function.
• The test is nonspecific and may be abnormal in various platelet disorders.

Assessment of Defects in Definitive Hemostatic Plug

• Evaluation of the secondary hemostatic plug focuses on coagulation factors responsible for fibrin formation.
• These tests identify abnormalities in the intrinsic, extrinsic, and common pathways of coagulation.

Clotting Time (CT)

• Clotting time measures the overall time required for blood to clot under controlled conditions. It is commonly assessed by the capillary tube method or the venous blood method.
• The normal range is 2 to 8 minutes by capillary method and 5 to 12 minutes by venous method.
• Prolonged clotting time suggests deficiency of one or more coagulation factors.
• Values exceeding 10 minutes require further evaluation to identify specific defects.

Prothrombin Consumption Test

• This test estimates the amount of prothrombin remaining in serum after clot formation.
• Normally, prothrombin is converted to thrombin during coagulation.
• Increased residual prothrombin indicates platelet deficiency or dysfunction, as platelets are essential for prothrombin utilization.

Prothrombin Time (PT)

• Prothrombin time evaluates the extrinsic and common pathways of coagulation.
• Tissue thromboplastin and calcium are added to plasma to initiate clotting.
• The normal range is 12 to 16 seconds.
• Prolongation suggests deficiency of factors II, V, VII, or X, or impairment of liver function. It is widely used to monitor oral anticoagulant therapy.

Partial Thromboplastin Time (PTT)

• Partial thromboplastin time assesses the intrinsic and common pathways. It involves addition of partial thromboplastin and calcium to plasma.
• The normal value ranges from 60 to 80 seconds.
• Prolongation indicates deficiency of factors XII, XI, IX, VIII, X, V, II, or I.

Activated Partial Thromboplastin Time (APTT)

• Activated partial thromboplastin time is a sensitive test for evaluating the intrinsic and common pathways of coagulation. It is more reliable than partial thromboplastin time due to standardized activation using contact agents.
• A phospholipid substitute and an activator such as kaolin are added to plasma, followed by calcium to initiate clotting.
• The normal range is 35 to 40 seconds.
• Prolongation indicates deficiency of factors XII, XI, IX, VIII, or X, or presence of inhibitors. It is especially useful in diagnosing hemophilia and for monitoring heparin therapy.

Thrombin Time (TT)

• Thrombin time evaluates the final step of coagulation, which is conversion of fibrinogen to fibrin.
• Thrombin is added directly to plasma, and the clotting time is measured.
• The normal value is 15 to 20 seconds.
• Prolongation suggests low fibrinogen levels, abnormal fibrinogen function, or presence of anticoagulants. It helps identify disorders affecting the final stage of clot formation.

Plasma Recalcification Time (PRT)

• Plasma recalcification time assesses the efficiency of the intrinsic coagulation pathway.
• Calcium is added to citrated plasma to initiate clotting.
• The test reflects activity of multiple clotting factors except factor VII and factor XIII.
• Normal values are 100 to 150 seconds for platelet-rich plasma and 135 to 240 seconds for platelet-poor plasma.
• Shorter clotting time in platelet-rich plasma occurs due to availability of platelet phospholipids.
• Prolongation indicates deficiency of intrinsic pathway factors such as XII, XI, IX, VIII, X, V, and II.

Clot Retraction Time

• Clot retraction time evaluates platelet function and the stability of the formed clot.
• Platelets contract and pull fibrin strands together, reducing clot size and expelling serum.
• Reduced or absent retraction indicates platelet dysfunction or thrombocytopenia.
• This test provides supportive information about platelet contribution to coagulation.

Abnormalities Of Coagulation

• Hemorrhagic disorders are classified into inherited and acquired conditions affecting hemostasis.
• Acquired disorders are more common than inherited forms and often involve platelet abnormalities.
• Common inherited defects include deficiency of factor VIII and factor IX, leading to impaired coagulation.
• Frequent acquired causes include thrombocytopenia, vitamin K deficiency, disseminated intravascular coagulation, and liver disease, all of which reduce effective clot formation.

Hemophilia A

Etiology

• Hemophilia A is a hereditary bleeding disorder caused by deficiency of factor VIII. It follows an X-linked recessive inheritance pattern, affecting mainly males.
• Females are typically carriers and are usually asymptomatic due to the presence of a normal second X chromosome. It is one of the most common inherited coagulation disorders, though less frequent than von Willebrand disease.

Clinical Features

• The disorder presents with increased bleeding tendency, often beginning in early childhood.
• Severe cases show spontaneous bleeding, particularly into joints and muscles.
• Hemarthrosis is a characteristic feature and may lead to chronic joint damage and deformity.
• Soft tissue hematomas are common and may occur even with minor trauma.
• In mild to moderate cases, bleeding is prolonged after injury or surgical procedures.
• Bleeding episodes may persist for several days despite initial clot formation.

Diagnosis

• Activated partial thromboplastin time is prolonged due to intrinsic pathway defect.
• Prothrombin time and bleeding time are usually within normal limits.
• Definitive diagnosis is made by measuring factor VIII activity in plasma.
• Reduced functional activity confirms the severity of the disorder.

Treatment

• Management involves replacement of deficient factor VIII to achieve hemostasis.
• Factor VIII concentrates are the treatment of choice for acute bleeding episodes.
• Fresh frozen plasma and cryoprecipitate may also be used when concentrates are unavailable.
• Drugs that impair platelet function, such as aspirin, should be avoided.
• Early treatment helps prevent complications such as joint deformities and disability.

Christmas Disease (Hemophilia B)

Etiology

• Hemophilia B is a hereditary bleeding disorder caused by deficiency of factor IX. It follows an X-linked recessive inheritance pattern, primarily affecting males.

Features

• Clinical manifestations are similar to those of hemophilia A.
• Patients develop hemarthrosis, soft tissue hematomas, and prolonged bleeding after trauma.
• Recurrent joint bleeding may lead to chronic joint damage.

Diagnosis

• Prothrombin time is usually normal, while partial thromboplastin time is prolonged.
• Diagnosis is confirmed by reduced factor IX activity in plasma.

Treatment

• Management involves replacement therapy with factor IX concentrates to control bleeding.

von Willebrand Disease

Etiology

• von Willebrand disease is the most common inherited bleeding disorder caused by deficiency or dysfunction of von Willebrand factor. It affects both males and females because inheritance is usually autosomal.
• von Willebrand factor is essential for platelet adhesion to damaged endothelium and acts as a carrier for factor VIII.
• Deficiency leads to impairment of both primary and secondary hemostasis.

Variants

• Type 1 is the most common form and involves partial quantitative deficiency, typically about 20 to 50 percent reduction.
• Type 2 includes qualitative defects with abnormal function of the factor.
• Type 3 is the most severe form with near-complete absence of the factor.
• Factor VIII activity is mildly reduced in type 1, variable in type 2, and markedly decreased in type 3.

Clinical Features

• The typical presentation includes mucocutaneous bleeding, such as nosebleeds and easy bruising.
• Patients may develop menorrhagia, gastrointestinal bleeding, and prolonged bleeding after minor injuries.
• Severe forms may show joint and muscle bleeding, similar to severe coagulation disorders.
• Symptoms vary depending on the type and severity of deficiency.

Diagnosis

• Bleeding time is often prolonged due to impaired platelet adhesion.
• Clotting tests may be normal or prolonged depending on factor VIII levels.
• Diagnosis is confirmed by quantitative and functional assays of von Willebrand factor.

Treatment

• Desmopressin is used in mild to moderate cases as it increases release of von Willebrand factor and factor VIII.
• Replacement therapy with von Willebrand factor concentrates is required in severe cases.
• Appropriate treatment reduces bleeding episodes and improves quality of life.

Disseminated Intravascular Coagulation (DIC)

Definition and Etiology

• Disseminated intravascular coagulation is a clinical syndrome characterized by widespread activation of coagulation within the circulation.
• Excess procoagulant activity overwhelms natural anticoagulant mechanisms, leading to uncontrolled clot formation. This condition is also termed consumption coagulopathy because clotting factors and platelets are rapidly depleted.
• Exposure of tissue factor is a major trigger that activates the extrinsic pathway.
• Secondary activation of fibrinolysis results in increased fibrin degradation products.
• Common causes include sepsis, obstetric complications, severe trauma, burns, envenomation, and incompatible blood transfusion.

Manifestations

• The disorder presents with a combination of thrombosis and bleeding.
• Widespread microvascular thrombosis leads to multiorgan dysfunction.
• Simultaneously, depletion of platelets and clotting factors causes severe bleeding.
• Enhanced fibrinolysis further contributes to bleeding tendency.

Diagnosis

• Laboratory findings show thrombocytopenia and reduced fibrinogen levels.
• There is prolongation of prothrombin time, activated partial thromboplastin time, and thrombin time.
• Elevated levels of D-dimer and fibrin degradation products indicate increased fibrinolysis.
• Diagnosis is supported by decreased coagulation factors and evidence of fibrin breakdown products.

Treatment

• Management requires prompt identification and treatment of the underlying cause.
• Replacement therapy with platelets and coagulation factors is given in bleeding patients.
• Supportive care helps maintain organ function and prevent complications.
• Early intervention is essential to reduce morbidity and mortality.

Thrombosis

• Thrombosis refers to formation of an intravascular clot within blood vessels.
• Under normal conditions, a balance between coagulation and anticoagulation prevents clot formation.
• Disruption of this balance leads to pathological clot development.
• Three major factors predispose to thrombosis:
• Endothelial injury promotes platelet adhesion and aggregation at the damaged site. It occurs in conditions such as hypertension and atherosclerosis.
• Stasis of blood flow slows circulation, allowing accumulation of clotting factors. It is common in prolonged immobility and venous disorders.
• Hypercoagulability increases tendency for clot formation due to elevated clotting factors.
• Platelet activation initiates thrombus formation, followed by fibrin deposition.
• Venous thrombosis is more common than arterial thrombosis.
• Examples include thrombosis in lower limb veins and deep vein thrombosis.
• Thrombi may also form in cardiac chambers and on valve surfaces.
• A major complication is thromboembolism, where fragments detach and travel in circulation.
• Emboli may lodge in organs such as brain, lungs, heart, or intestines. This can result in infarction, leading to stroke, pulmonary embolism, or myocardial infarction.
• Prevention includes use of anticoagulants and antiplatelet agents in high-risk individuals.